Evommune Inc.
EVMN | NYSE
$6.20
-$0.53 (-7.88%)
Nov 2, 2026, 10:59 AM ET · Market open
Company Profile
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
Key Executives
| Name | Position |
|---|---|
| Luis C. Pena | Founder, President, Chief Executive Officer & Director |
| Kyle Carver | Chief Financial Officer |
| Daniel J. Burge | Senior Vice President of Clinical Development |
| Eugene Andrew Bauer | Co-Founder, Chief Medical Officer & Director |
| Gregory S. Moss | Chief Business & Legal Officer, Corporate Secretary and Chief Compliance Officer |
| J. Mark Jackson | Senior Vice President of Clinical Development |
| Janice Drew | Chief of Development Operations |
| Jeegar Patel | Chief Scientific Officer |
| Lou Sehl | Senior Vice President of Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 01, 2026 | 8-K | Current Report |
| Sep 23, 2026 | 8-K | Current Report |
| Sep 15, 2026 | 8-K | Current Report |
| Sep 09, 2026 | 424B3 | Filing |
| Sep 09, 2026 | 8-K | Current Report |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 06, 2026 | 424B3 | Filing |
| Aug 06, 2026 | 10-Q | Quarterly Report |
| Aug 06, 2026 | 8-K | Current Report |
Evommune Inc.
| Country | United States |
| IPO Date | Nov 6, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 48 |
| CEO | Luis C. Pena |
Contact Details
1841 Page Mill Road Palo Alto,
California 94304 United States
Stock Details
| Ticker Symbol | EVMN |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0002044725 |
| CUSIP Number | 30054Y107 |
| ISIN Number | US30054Y1073 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove EVMN